TAGAMET HB Rx-TO-OTC SWITCH HINGES ON OUTCOME OF DRUG INTERACTION STUDIES
This article was originally published in The Tan Sheet
TAGAMET HB Rx-TO-OTC SWITCH HINGES ON OUTCOME OF DRUG INTERACTION STUDIES requested by FDA's Nonprescription Drugs and Gastrointestinal Drugs Advisory Committees at a joint meeting July 27-28. The panel was particularly interested in cimetidine's interaction with theophylline, an anti-asthma drug, and Upjohn's prescription sleep-aid Halcion (triazolam).
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC